Pharmacokinetic Properties of Fast-acting Insulin Aspart Administered in Different Subcutaneous Injection Regions: Response to the commentary by Nuggehally R. Srinivas

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical drug investigation

• Publication date

  2017-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40261-017-0539-7PMID 28597216
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes

  2017cited by this paper
• Pharmacodynamics of Insulin Preparations Administered in Different Subcutaneous Injection Sites: Are There Differences Between Healthy Subjects Versus Diabetic Patients?

  2017cited by this paper
• Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions

  2017cited by this paper
• Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)

  2017cited by this paper
• Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus.

  2016cited by this paper
• Euglycaemic glucose clamp: what it can and cannot do, and how to do it

  2016cited by this paper
• A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance

  2014cited by this paper
• Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region

  2012cited by this paper
• The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back

  2008cited by this paper
• Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus.

  2006cited by this paper
• A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4).

  2005cited by this paper
• Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.

  1999cited by this paper
• Injection Site Effects on the Pharmacokinetics and Glucodynamics of Insulin Lispro and Regular Insulin

  1996cited by this paper
• Effects of the Anatomical Region Used for Insulin Injections on Glycemia in Type I Diabetes Subjects

  1993cited by this paper
• Impact of injection sites for soluble insulin on glycaemic control in Type 1 (insulin-dependent) diabetic patients treated with a multiple insulin injection regimen

  1993cited by this paper
• Relationship Between Absorption of Radiolabeled Soluble Insulin, Subcutaneous Blood Flow, and Anthropometry

  1992cited by this paper
• The effect of subcutaneous injection site on absorption of human growth hormone: abdomen versus thigh

  1991cited by this paper
• Absorption Kinetics and Biologic Effects of Subcutaneously Injected Insulin Preparations

  1982cited by this paper
• Insulin absorption from the abdomen and the thigh in healthy subjects during rest and exercise: Blood glucose, plasma insulin, growth hormone, adrenaline and noradrenaline levels

  1982cited by this paper
• Alterations in Insulin Absorption and in Blood Glucose Control associated with Varying Insulin Injection Sites in Diabetic Patients

  1981cited by this paper
• Alterations in Insulin Absorption and in Blood Glucose Control Associated with Varying Insulin Injection Sites in Diabetic Patients

  1980cited by this paper

• Pharmacodynamics of Insulin Preparations Administered in Different Subcutaneous Injection Sites: Are There Differences Between Healthy Subjects Versus Diabetic Patients?

  2017cites this paper